Earnings call transcript: Neuropace Q2 2025 sees revenue rise; stock gains 2.7%

Neuropace (NPCE) reported robust Q2 2025 revenue of $23.5 million, a 22% year-over-year increase that slightly exceeded analyst expectations, leading to a 2.7% after-hours stock gain despite a wider-than-forecasted loss per share. The company raised its full-year revenue guidance to $94M-$98M and its gross margin outlook, signaling confidence in its RNS system's sustained 20%+ growth, strategic initiatives like Project CARE, and ongoing clinical development, including targeted 2025 FDA submissions for IGE and pediatric indications. Furthermore, a successful debt refinancing and a favorable CMS reimbursement decision for its RNS procedures enhance financial flexibility and stability, reinforcing investor optimism despite current unprofitability.

Analysis

Neuropace (NPCE) delivered a strong Q2 2025 performance characterized by robust top-line growth that overshadowed a wider-than-expected net loss, signaling to investors that its strategic priorities are yielding results. Revenue grew 22% year-over-year to $23.5 million, marginally beating forecasts and prompting management to raise full-year revenue guidance to a range of $94 million to $98 million. This growth was driven by a 16% increase in core RNS System sales, supported by expansion initiatives like Project CARE. Despite an earnings per share miss at -$0.26, the market responded positively with a 2.7% after-hours stock gain, focusing instead on the impressive gross margin of 77.1%, improved free cash flow of -$2.3 million, and the company's raised gross margin outlook to 75-76%. Key de-risking events further bolstered this positive sentiment, including a successful debt refinancing that improves financial flexibility and a favorable CMS decision that maintains the current reimbursement structure, avoiding near-term uncertainty.

The company's future growth hinges on significant clinical and technological catalysts. Although the NAUGHTLIST trial for an IGE indication did not meet its primary endpoint due to a pre-specified analysis method, it demonstrated highly statistically significant (p<0.001) and clinically meaningful results on key secondary endpoints, with seizure reduction data signaling better than 80% at 18-24 months. Management remains confident in a 2025 FDA submission for a broad indication based on the totality of this data. This is complemented by plans for a pediatric market submission in 2025 and the ongoing development of AI-powered tools, which leverage a formidable proprietary dataset of over 22 million recorded events, creating a substantial competitive moat that is being further validated through partnerships with firms like UCB.

Key Decisions for Investors

• Investors should weigh the strong 22% revenue growth and raised guidance against the persistent net losses; the market's positive reaction suggests a focus on the long-term growth story, but the path to profitability remains a critical metric to monitor.
• The 2025 FDA submission for the IGE indication is a pivotal catalyst; a favorable regulatory outcome could significantly de-risk the stock and unlock a new market, making the company's engagement with the FDA a key event to watch.
• Given the stock's noted volatility and that it is reportedly trading above its fair value, it may be prudent to consider the elevated risk profile, while acknowledging that analyst price targets of $15-$20 suggest significant potential upside if execution continues.
• Consider the long-term strategic value of Neuropace's data moat and AI initiatives, as the ability to monetize its unique dataset through pharmaceutical partnerships and enhance its product with AI represents a distinct and durable competitive advantage.